Lupin receives Form 483 after product contaminated with human hair
US FDA issues Lupin with a Form 483 based on three observations during a recent inspection at its Aurangabad site.
Top Headlines
Global Industry News
-
US Senate authorises increased spending on pandemic flu products
from BioPharma-Reporter.com
-
WuXi in $3bn deal to manufacture 'first of its kind' vaccine
from BioPharma-Reporter.com
-
Advarra aims to accelerate pediatric trials in an agreement
from Outsourcing-Pharma.com
-
Combining capabilities to grow: Navitas acquires KAI Research
from Outsourcing-Pharma.com
Hot Topics
-
US-EMA mutual recognition has two months to go and four countries left
Globalisation
-
Thermo Fisher’s M&A spend continues with €90m GSK facility
Mergers and Acquisitions
-
‘Speed and efficiency’: WuXi STA outlines benefits of integrated CMC services
Globalisation
-
AstraZeneca gets FDA green light for diabetes adjunct treatment
Lifecycle Management
